- Michael Aschner, Albert Einstein College of Medicine
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Catherine MT Sherwin, University of Utah
- Christopher Morrey, BioMed Central
Toxicological study of the intranasal administration of large overdoses of glucagon nasal powder to rats and dogs for 28 consecutive days suggests it to be well tolerated and result in only mild to moderate fully reversible histological changes to nasal mucosa in some animals.
Population-based analysis highlights increased analgesic use in Germany in the last decade and significant relationships between analgesic use and factors including age, gender, socio-economic status and health behavior.
Pegylated phosphatidylserine-containing liposome (PEG-PSL) treatment does not suppress chronic inflammation in collagen induced arthritis in mice and suggests the important contribution of TGF-β1 and other cytokines in the mechanism of action.
A retrospective cohort study quantifying the preventive effect of antihypertensive treatment using data from specific health check-ups and health insurance claims suggests that treatment with renin-angiotensin inhibitors is potentially useful for preventing the development of diabetic kidney disease.
A single-blind phase 1B proof of concept study suggests treatment with multiple rising doses of PUR118 is safe with three applications within 25 h prior to the ozone challenge having small effects on ozone-induced airway inflammation.
A prospective cohort study suggests that early cadmium exposure is associated with lower birth weight and that maternal cadmium exposure in early pregnancy may alter DNA methylation at multiple differentially methylated regions in offspring with sex and possibly race/ethnic-specific effects.
BMC Pharmacology and Toxicology 2015, 16:21
News from the web
- 27 November 2015
- Known enzymes could be treasure trove for drug discovery
- 26 November 2015
- Simplifying the UK medicines manufacturing landscape
- 25 November 2015
- Prices rise for prescription dermatologic drugs
- 25 November 2015
- Plant defense as a biotech tool
- 25 November 2015
- Chemical design made easier
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
BMC Pharmacology and Toxicology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
BMC series blog
- 18 November 2015
- Adélie penguins – the climate change winners?
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.